Genetic dissection of intratumor heterogeneity of PD-L1 expression in EGFR-mutated lung adenocarcinoma

被引:2
|
作者
Kunimasa, Kei [1 ]
Hirotsu, Yosuke [2 ]
Amemiya, Kenji [2 ]
Honma, Keiichiro [3 ]
Nakamura, Harumi [4 ]
Nishino, Kazumi [1 ]
Omata, Masao [2 ,5 ]
机构
[1] Osaka Int Canc Inst, Dept Thorac Oncol, 3-1-69 Otemae Chuoku, Osaka, Osaka 5418567, Japan
[2] Yamanashi Cent Hosp, Genome Anal Ctr, Kofu, Yamanashi, Japan
[3] Osaka Int Canc Inst, Dept Diagnost Pathol & Cytol, Osaka, Japan
[4] Osaka Int Canc Inst, Lab Genom Pathol, Osaka, Japan
[5] Univ Tokyo, Tokyo, Japan
基金
日本学术振兴会;
关键词
EGFR mutation; intratumor heterogeneity; PD-L1; expression; tumor infiltrating lymphocytes; MUTATIONS; GENOME; CELLS;
D O I
10.1111/1759-7714.15038
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In this study, we investigated the association between PD-L1 expression in tumor cells and underlying genetic mutations, which was analyzed in detail using laser microdissection and next-generation sequencing analysis. To investigate whether driver mutations are involved in the background of PD-L1 expression, the EGFR major activating mutation was selected as the most frequent driver mutation. Surgical resection specimens were used to extract sufficient amounts of nucleic acids for analysis, and the high tumor proportion score (TPS:100%) and low (TPS: 0%) PD-L1-expressing parts of the tumor were each laser microdissected to examine the association between PD-L1 expression heterogeneity and genetic mutations within the same tumor. The association between PD-L1 heterogeneity and gene mutations within the same tumor was investigated. Analysis showed no association between PD-L1 expression heterogeneity and genetic variants, which were found to be almost identical. However, PD-L1 expression was found to be associated with the number of tumor infiltrating lymphocytes (TILs) present in the tumor, which may be related to whether or not lymphocytes can infiltrate into the tumor depending on the tumor histological type (solid pattern, lepidic pattern, etc.) and other factors.
引用
收藏
页码:2210 / 2215
页数:6
相关论文
共 50 条
  • [31] PD-L1 score as a prognostic biomarker in Asian patients with early-stage, EGFR-mutated lung cancer.
    Saw, Stephanie
    Lai, Gillianne
    Tan, Aaron C.
    Zhou, Siqin
    Ang, Mei-Kim
    Lim, Wan-Teck
    Kanesvaran, Ravindran
    Tan, Wan Ling
    Rajasekaran, Tanujaa
    Chan, Johan
    Teh, Yi Lin
    Ong, Boon-Hean
    Takano, Angela M.
    Tan, Eng Huat
    Tan, Sze Huey
    Tan, Daniel Shao-Weng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] mRNA expression profile specific to micropapillary element in EGFR-mutated lung adenocarcinoma
    Koike, Chihiro
    Matsumura, Mai
    Mitsui, Hideaki
    Kataoka, Toshiaki
    Umeda, Shigeaki
    Tateishi, Yoko
    Suzuki, Takehisa
    Arai, Hiromasa
    Okudela, Koji
    CANCER SCIENCE, 2018, 109 : 1409 - 1409
  • [33] Implications of EGFR expression in MAPK dependency and adaptive immunity status of EGFR-mutated lung adenocarcinoma
    Torasawa, Masahiro
    Yoshida, Tatsuya
    Shiraishi, Kouya
    Yagishita, Shigehiro
    Uehara, Yuji
    Miyakoshi, Jun
    Higashiyama, Ryoko Inaba
    Mochizuki, Akifumi
    Matsumoto, Yuji
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Hamamoto, Ryuji
    Yamamoto, Noboru
    Watanabe, Shun-ichi
    Yatabe, Yasushi
    Takahashi, Kazuhisa
    Kohno, Takashi
    Ohe, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Genetic and epigenetic intratumor heterogeneity of lung adenocarcinoma
    Zhao, Wei
    Hua, Xing
    Zhang, Tongwu
    Consonni, Dario
    Pesatori, Angela Cecilia
    Shi, Jianxin
    Landi, Maria Teresa
    CANCER RESEARCH, 2019, 79 (13)
  • [35] Clinicopathological Characteristics of PD-L1 Expression in Lung Adenocarcinoma
    Wu, Shafei
    Shi, Xiaohua
    Sun, Jian
    Liu, Yuanyuan
    Liang, Zhiyong
    Zeng, Xuan
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S816 - S816
  • [36] EGFR signaling regulates aerobic glycolysis in EGFR-mutated lung adenocarcinoma
    Makinoshima, Hideki
    Takita, Masahiro
    Matsumoto, Shingo
    Yagishita, Atsushi
    Owada, Satoshi
    Esumi, Hiroyasu
    Tsuchihara, Katsuya
    CANCER RESEARCH, 2014, 74 (19)
  • [37] Mucinous lung adenocarcinoma, particularly referring to EGFR-mutated mucinous adenocarcinoma
    WakejiMa, Ryo
    Inamura, Kentaro
    Ninomiya, Hironori
    Nagano, Hiroko
    Mun, Mingyon
    Okumura, Sakae
    Okubo, Kenichi
    Ishikawa, Yuichi
    PATHOLOGY INTERNATIONAL, 2020, 70 (02) : 72 - 83
  • [38] PD-L1 Induced Resistance to EGFR-TKIs in Lung Adenocarcinoma
    Yi, G.
    Zhang, X.
    Li, S.
    Liu, L.
    Yuan, P.
    Yang, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S629 - S629
  • [39] Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer
    Olivier Bylicki
    Nicolas Paleiron
    Jacques Margery
    Florian Guisier
    Alain Vergnenegre
    Gilles Robinet
    Jean-Bernard Auliac
    Radj Gervais
    Christos Chouaid
    Targeted Oncology, 2017, 12 : 563 - 569
  • [40] Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer
    Bylicki, Olivier
    Paleiron, Nicolas
    Margery, Jacques
    Guisier, Florian
    Vergnenegre, Alain
    Robinet, Gilles
    Auliac, Jean-Bernard
    Gervais, Radj
    Chouaid, Christos
    TARGETED ONCOLOGY, 2017, 12 (05) : 563 - 569